Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression
Authors:
Open Access
- 3 May 2022
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (5) , e0267027
Abstract
ErbB3 (HER3), a member of the HER family, is overexpressed in various cancers and plays an important role in cell proliferation and survival. Certain HER3 mutations have also been identified as oncogenic drivers, making them potential therapeutic targets. In the current study, antitumor activity of patritumab deruxtecan (HER3-DXd), a HER3 directed antibody drug conjugate, was evaluated in tumor models with clinically reported HER3 mutations. MDA-MB-231, a HER3-negative human triple-negative breast cancer cell line, was transduced with lentiviral vectors encoding HER3 wild type (HER3WT), one of 11 HER3 mutations, or HER3 empty vector (HER3EV), in the presence/absence of HER2 overexpression. Targeted delivery of HER3-DXd was assessed using cell-surface binding, lysosomal trafficking, and cell-growth inhibition assays. HER3-DXd bound to the surface of HER3WT and mutant cells in a similar, concentration-dependent manner but not to HER3EV. HER3-DXd was translocated to the lysosome, where time- and concentration-dependent signals were observed in the HER3 mutant and HER3WT cells. HER3-DXd inhibited the growth of HER3WT and HER3 mutant cells. HER3-DXd activity was observed in the presence and absence of HER2 overexpression. These data suggest that HER3-DXd may have activity against tumors expressing wild type HER3 or clinically observed HER3 mutations, supporting further clinical evaluation.Keywords
Funding Information
- Daiichi-Sankyo
This publication has 19 references indexed in Scilit:
- Activating HER3 mutations in breast cancerOncotarget, 2018
- HER kinase inhibition in patients with HER2- and HER3-mutant cancersNature, 2018
- Genomic alterations of ERBB receptors in cancer: clinical implicationsOncotarget, 2017
- Activating HER2 mutations as emerging targets in multiple solid cancersESMO Open, 2017
- Genomic Characterization of Primary Invasive Lobular Breast CancerJournal of Clinical Oncology, 2016
- Oncogenic ERBB3 Mutations in Human CancersCancer Cell, 2013
- HER3 Overexpression and Survival in Solid Tumors: A Meta-analysisJNCI: Journal of the National Cancer Institute, 2012
- The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeuticsSeminars in Cell & Developmental Biology, 2010
- Novel anticancer targets: revisiting ERBB2 and discovering ERBB3Nature Reviews Cancer, 2009
- ErbB receptors and signaling pathways in cancerCurrent Opinion in Cell Biology, 2009